Alnylam Pharmaceuticals (NASDAQ: ALNY) insider transactions

In the twelve months to 10 November 2026, executives and directors of Alnylam Pharmaceuticals reported 279 open-market sales of 119,540 shares ($44.0m) and 0 open-market purchases, by 8 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Alnylam Pharmaceuticals shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
2 October 2026	Supran Bryan	EVP, CLO and Secretary	Open-market sale	−1,758	$226.88	12,807	Form 4
19 September 2026	Greenstreet Yvonne	Chief Executive Officer	Grant or award	+107	—	95,802	Form 4
1 June 2026	Pyott David E I	Director	Option exercise, 10b5-1 plan	+3,830	—	5,412	Form 4
1 June 2026	Pyott David E I	Director	Open-market sale, 10b5-1 plan	−921	$297.71	4,491	Form 4
1 June 2026	Pyott David E I	Director	Open-market sale, 10b5-1 plan	−1,175	$298.91	3,316	Form 4
1 June 2026	Pyott David E I	Director	Open-market sale, 10b5-1 plan	−1,222	$299.87	2,094	Form 4
1 June 2026	Pyott David E I	Director	Open-market sale, 10b5-1 plan	−495	$300.72	1,599	Form 4
1 June 2026	Pyott David E I	Director	Open-market sale, 10b5-1 plan	−17	$302.65	1,582	Form 4
20 May 2026	Arbuckle Stuart A	Director	Grant or award	+671	—	671	Form 4
20 May 2026	Ausiello Dennis A	Director	Grant or award	+671	—	1,582	Form 4
20 May 2026	Brandicourt Olivier	Director	Grant or award	+671	—	1,446	Form 4
20 May 2026	Hamburg Margaret A	Director	Grant or award	+671	—	1,582	Form 4
20 May 2026	Kellogg Peter N	Director	Grant or award	+671	—	1,446	Form 4
20 May 2026	Pyott David E I	Director	Grant or award	+671	—	1,582	Form 4
20 May 2026	Reitan Colleen F	Director	Grant or award	+671	—	1,446	Form 4
20 May 2026	Schulman Amy W	Director	Grant or award	+838	—	24,049	Form 4
20 May 2026	Sigal Charles Elliott	Director	Grant or award	+671	—	1,446	Form 4
13 May 2026	Schulman Amy W	Director	Option exercise	+11,250	$70.20	23,211	Form 4
6 April 2026	McLaughlin Melissa	Chief Human Resources Officer	Open-market sale, 10b5-1 plan	−56	$320.14	11,673	Form 4
6 April 2026	McLaughlin Melissa	Chief Human Resources Officer	Open-market sale, 10b5-1 plan	−909	$329.76	10,764	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Alnylam Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.